Search results for: 'security product'

30 Mar 2023  |  North America  |  Customer Research

Global Laboratory Product Purchasing Trends, 2022–2023

End–user Perspectives on Laboratory Spending Reveals Modest 2023 Budget Increases Following robust 2022 Spending

Infographics

×

Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey from October to November 2022 examining their laboratories’ product purchasing process in 2022 and expectations for 2023. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. The study presents year-over-...

Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2018 that centered around the state of their laboratories in 2018 and their expectations for 2019. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year-o...

Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2019 that centered around the state of their laboratories in 2019 and their expectations for 2020. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year-o...

Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in September 2020 that centered on the state of their laboratories in 2020 and their expectations for 2021. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year-ove...

Full product development IVD CMO comprises companies that partner with OEMs and support them in the development of IVD devices, ranging from concept to commercialization. IVD companies are continuously looking at new ways to optimize resources due to rising cost pressures and regulatory complexities, prompting industry participants to adopt innovat...

The growth trajectory of the global life sciences industry has benefited from a combination of novel technologies such as CRISPR-Cas9, microbiome and single-cell, relaxation of entry barriers in markets like China, and better-defined regulatory frameworks around next-generation therapies and companion diagnostics. A common denominator of growth a...

The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus o...

Healthcare is rapidly becoming patient-centric, focusing on outcomes and value. This offers clinical diagnostics players opportunities to advance their instrument, assay, and informatics capabilities to address unmet clinical needs and increase the precision diagnostics portfolio. Advances in next-generation sequencing-based companion diagnosti...

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and translation of blood-based neurology biomarkers, sustai...